Call for Abstract

2nd World Conference on Vaccine and Immunology, will be organized around the theme “Highlights of Latest Technologies and Innovations in Vaccines and Immunology”

World Vaccine Meet 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in World Vaccine Meet 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Hepatitis A vaccine
  • Track 1-2Measles vaccine
  • Track 1-3Anthrax vaccine
  • Track 1-4BCG vaccine
  • Track 2-1anatomical pathology
  • Track 2-2clinical pathology
  • Track 2-3Antitumor Effector Cells and Regulation of Tumor Immunity.
  • Track 2-4Tumor-Associated Antigens
  • Track 3-1Lupus
  • Track 3-2Scleroderma
  • Track 3-3Certain types of hemolytic anemia
  • Track 3-4Type one diabetes
  • Track 3-5Vasculitis
  • Track 4-1Breast cancer vaccine.
  • Track 4-2Ovarian cancer vaccine.
  • Track 4-3Prostate cancer vaccine
  • Track 5-1Diphtheria, Tetanus, Pertussis (DTaP)
  • Track 5-2Polio (IPV)
  • Track 5-3Measles, Mumps, Rubella (MMR)
  • Track 5-4Chickenpox (Varicella)
  • Track 5-5Hepatitis A and B
  • Track 6-1T Cells Immune
  • Track 6-2Complex Monospecific Antibody
  • Track 6-3Immune Response
  • Track 6-4VirusAntigen
  • Track 7-1Adenovirus vaccine
  • Track 7-2Coxsackie B virus vaccine
  • Track 7-3Caries vaccine
  • Track 7-4Ehrlichiosis vaccine
  • Track 7-5Malaria vaccine
  • Track 7-6Schistosomiasis vaccine
  • Track 8-1Hib conjugate vaccine
  • Track 8-2Typhoid conjugate vaccine
  • Track 9-1Hepatitis A.
  • Track 9-2Hepatitis B.
  • Track 9-3Typhoid and paratyphoid fever
  • Track 9-4Meningococcal disease
  • Track 10-1Diphtheria, Tetanus, Pertussis (DTaP)
  • Track 10-2Polio (IPV)
  • Track 10-3Measles, Mumps, Rubella (MMR)
  • Track 10-4Chickenpox (Varicella)
  • Track 10-5Hepatitis A and B
  • Track 11-1Glucocorticoids
  • Track 11-2Gastroenteropancreatic neuroendocrine tumours( GEP-NET)
  • Track 11-3Chemotherapy
  • Track 11-4Radio nuclide therapy
  • Track 11-5Psychoneuroimmunological effects
  • Track 12-1The measles, mumps, rubella combination vaccine (MMR)
  • Track 12-2 The preservative thimerosal, which was never present in MMR but was present in several vaccines used in the 1990s—it has since been removed from all routinely used childhood vaccines with the exception of flu.
  • Track 13-1tetanus toxoid
  • Track 13-2reduced diphtheria toxoid
  • Track 13-3acellular pertussis (Tdap) vaccine
  • Track 13-4injectable influenza vaccine
  • Track 14-1The acute-phase reaction
  • Track 14-2Sickness behaviour
  • Track 14-3The pain program
  • Track 14-4The stress response
  • Track 15-1the egg-based vaccines
  • Track 15-2cell-based vaccines
  • Track 15-3Hepatitis B
  • Track 15-4bacterial vaccines, viral vaccines, parasite vaccines
  • Track 16-1Hypersensitivity
  • Track 16-2Autoimmune Toxicology
  • Track 16-3Food Induced Immuntoxicity
  • Track 16-4Allergic Reactions
  • Track 17-1Immunopathogenesis of Asthma
  • Track 17-2Immune Reconstitution Disorders in patients with HIV infection
  • Track 17-3Immunopathogenesis of Glomerular diseases
  • Track 17-4Inflammatory Myopathies
  • Track 18-1Genome informatics
  • Track 18-2Infectious disease informatics
  • Track 19-1Chemotherapy
  • Track 19-2Progenitor Cell
  • Track 19-3Cell Lines
  • Track 19-4Embryonic Stem Cell
  • Track 20-1immunodeficiency, in which parts of the immune system fail to provide an adequate response (examples include chronic granulomatous disease and primary immune diseases)
  • Track 20-2isotopic (radio) or fluorescent label
  • Track 20-3color-forming enzyme
  • Track 21-1influenza
  • Track 21-2pneumoniae
  • Track 21-3herpes zoster
  • Track 21-4tetanus
  • Track 22-16-succinylmorphine (6-SM)
  • Track 22-2bovine serum albumin (BSA)
  • Track 22-3anticocaine vaccine
  • Track 22-4cocaine diamide hapten (GND)
  • Track 23-1Antitumor Effector Cells and Regulation of Tumor Immunity
  • Track 23-2Tumor-Associated Antigens
  • Track 23-3Tumor-Associated Immunosuppression
  • Track 23-4Mechanisms of Tumor Rejection and Modulation of Antitumor Responses
  • Track 23-5Pathobiology of Immune System Malignancies
  • Track 24-1 Asthma in children younger than 12 years: Initiating therapy and monitoring control
  • Track 24-2 Food allergy in college and university students: Overview and management
  • Track 24-3 Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma
  • Track 24-4Overview of therapeutic monoclonal antibodies
  • Track 24-5 Component testing for pollen-related, plant-derived food allergies